Fulltext

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings

Tschumi, Sibylle ; Gugger, Mathias ; Bucher, Barbara ; Riedl, Magdalena ; Simonetti, Giacomo

In: Pediatric Nephrology, 2011, vol. 26, no. 11, p. 2085-2088

Add to personal list
    Title
    • Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings
    Author
    • Tschumi, Sibylle. Division of Paediatric Nephrology, Children's Hospital, University of Bern, 3010, Berne, Switzerland
    • Gugger, Mathias. Department of Pathology, University of Bern, Bern, Switzerland
    • Bucher, Barbara. Division of Paediatric Nephrology, Children's Hospital, University of Bern, 3010, Berne, Switzerland
    • Riedl, Magdalena. Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria
    • Simonetti, Giacomo. Division of Paediatric Nephrology, Children's Hospital, University of Bern, 3010, Berne, Switzerland
    Document Type
    • Postprint
    OAI-PMH Identifier
    • oai:doc.rero.ch:310821
    Summary
    Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated with defective regulation of the alternative complement pathway. The prognosis for patients with aHUS is poor, and plasma exchange represents the first-line therapy. Eculizumab is a humanized monoclonal anti-C5 antibody that prevents the activation of the terminal complement pathway. Here, we report the case of a 9-year-old girl with frequent relapsing aHUS due to heterozygous factor H mutation who was initially treated with plasma exchange three times per week with 150% plasma exchange volume. This treatment frequently caused allergic reactions and school absences. Because any reduction in the frequency of plasma exchange immediately induced relapses of the aHUS, treatment with eculizumab, 600mg every 2weeks, was started and plasma exchange completely stopped. On this drug regimen the patient showed no evidence of disease activity during a period of more than 24months. Renal function improved, proteinuria disappeared, the number of antihypertensive medications could be decreased, and the quality of life increased substantially. The inhibition of the terminal complement pathway by eculizumab was also confirmed by renal biopsy, which showed the absence of thrombotic microangiopathy 2months after the initiation of eculizumab therapy. This case illustrates the long-term favorable outcome of aHUS with eculizumab treatment